Meeting
2019 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.
Authors
Jaume Mora
Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain
Jaume Mora , Brian H. Kushner , Miguel Angel Flores , Vicente Santa-María , Moira Garraus , Ellen M. Basu , Stephen S. Roberts , Alicia Castañeda , Maite Gorostegui , Nai-Kong V. Cheung , Shakeel Modak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03189706
Citation
J Clin Oncol 37, 2019 (suppl; abstr 10025)
DOI
10.1200/JCO.2019.37.15_suppl.10025
Abstract #
10025
Poster Bd #
407
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak
Poster
2024 ASCO Annual Meeting
Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma.
First Author: Cristina Larrosa
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan
Poster
2016 ASCO Annual Meeting
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
First Author: Steven G. DuBois